Brief: Supernus Pharmaceuticals To Acquire Sage Therapeutics, Strengthening Its Neuropsychiatry Product Portfolio
16/06/2025 12:43
June 16 (Reuters) - Supernus Pharmaceuticals Inc SUPN.O: SUPERNUS PHARMACEUTICALS TO ACQUIRE SAGE THERAPEUTICS, STRENGTHENING ITS NEUROPSYCHIATRY PRODUCT PORTFOLIO UPFRONT CASH PAYMENT OF $8.50 PER SHARE EXPECTED TO BE SIGNIFICANTLY ACCRETIVE IN 2026 WITH POTENTIAL COST SYNERGIES OF UP TO $200 MILLION ON AN ANNUAL BASIS DEALFOR AN AGGREGATE OF UP TO APPROXIMATELY $795 MILLION OR $12.00 PER SHARE Source text: ID:nGNX1DFSm7 Further company coverage: SUPN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Supernus Pharmaceuticals
See all newsHuron Consulting poised to hit fresh record ahead of S&P SmallCap addition
Brief: S&P Dow Jones Indices Msg Rangers And Huron Consulting Group Set To Join S&P Smallcap 600
Brief: Supernus Pharmaceuticals Says FDA Grants Seven Years Orphan-Drug Exclusivity For Onapgo
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE -Micron Technology, Ares Management, Boeing